Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602363 · ClinicalTrials.gov registry record · Phase 1
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
A Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Carna Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 13
- Study locations
NCT05602363: Recruiting Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Carna Biosciences.
NCT05602363 is a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Carna Biosciences. The registered enrollment target is 120 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (34% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05602363, a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Carna Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Primary Outcome
Dose escalation
Conditions Studied
Interventions
- DRUG Docirbrutinib
Study Locations (13)
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Moffitt Cancer Center - Tampa
Texas
- Oncology Consultants - Houston
- University of Texas MD Anderson Cancer Center - Houston
California
- UC Irvine Health - Orange
Illinois
- Northwestern Memorial Hospital - Chicago
Indiana
- American Oncology Partners - Fort Wayne
Maryland
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center - Baltimore
Massachusetts
- University of Massachusetts Memorial Medical Center - Worcester
New York
- Optum Medical Care PC - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT05602363 shows while recruiting
NCT05602363 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (34% lower).
The record links to 8 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Docirbrutinib is the first listed.
NCT05602363 lists 13 locations in 11 states (Florida, Texas, California).
Frequently Asked Questions
What is clinical trial NCT05602363 about?
NCT05602363 is a clinical study titled "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma". This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
What is the current status of trial NCT05602363?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-08-01. Estimated completion is 2027-09.
What conditions does trial NCT05602363 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT05602363?
The interventions under investigation include: Docirbrutinib (DRUG).
Who is sponsoring clinical trial NCT05602363?
This trial is sponsored by Carna Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05602363 being conducted?
This trial has 13 study locations across California, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05602363's enrollment target sits among peer trials
120 56th of 187 higher than 130 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI